1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Obesity	_	_	NN	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	related	_	_	JJ	_	_	_	_	_
4	disorders	_	_	NNS	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	widely	_	_	RB	_	_	_	_	_
7	perceived	_	_	VBN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	both	_	_	CC	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	public	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	scientific	_	_	JJ	_	_	_	_	_
15	community	_	_	NN	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	major	_	_	JJ	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	growing	_	_	VBG	_	_	_	_	_
21	threat	_	_	NN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	global	_	_	JJ	_	_	_	_	_
24	human	_	_	JJ	_	_	_	_	_
25	health	_	_	NN	_	_	_	_	_
26	;	_	_	:	_	_	_	_	_
27	more	_	_	JJR	_	_	_	_	_
28	than	_	_	IN	_	_	_	_	_
29	2	_	_	CD	_	_	_	_	_
30	billion	_	_	CD	_	_	_	_	_
31	people	_	_	NNS	_	_	_	_	_
32	worldwide	_	_	RB	_	_	_	_	_
33	are	_	_	VBP	_	_	_	_	_
34	currently	_	_	RB	_	_	_	_	_
35	overweight	_	_	JJ	_	_	_	_	_
36	or	_	_	CC	_	_	_	_	_
37	obese	_	_	JJ	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	obesity	_	_	NN	_	_	_	_	_
41	is	_	_	VBZ	_	_	_	_	_
42	associated	_	_	VBN	_	_	_	_	_
43	with	_	_	IN	_	_	_	_	_
44	an	_	_	DT	_	_	_	_	_
45	increased	_	_	VBN	_	_	_	_	_
46	hazard	_	_	NN	_	_	_	_	_
47	for	_	_	IN	_	_	_	_	_
48	a	_	_	DT	_	_	_	_	_
49	range	_	_	NN	_	_	_	_	_
50	of	_	_	IN	_	_	_	_	_
51	ailments	_	_	NNS	_	_	_	_	_
52	,	_	_	,	_	_	_	_	_
53	including	_	_	VBG	_	_	_	_	_
54	type-2	_	_	JJ	_	_	_	_	_
55	diabetes	_	_	NNS	_	_	_	_	_
56	,	_	_	,	_	_	_	_	_
57	cardiovascular	_	_	JJ	_	_	_	_	_
58	diseases	_	_	NNS	_	_	_	_	_
59	and	_	_	CC	_	_	_	_	_
60	hypertension	_	_	NN	_	_	_	_	_
61	,	_	_	,	_	_	_	_	_
62	multiple	_	_	JJ	_	_	_	_	_
63	cancer	_	_	NN	_	_	_	_	_
64	types	_	_	NNS	_	_	_	_	_
65	,	_	_	,	_	_	_	_	_
66	chronic	_	_	JJ	_	_	_	_	_
67	inflammatory	_	_	JJ	_	_	_	_	_
68	diseases	_	_	NNS	_	_	_	_	_
69	,	_	_	,	_	_	_	_	_
70	dementia	_	_	NN	_	_	_	_	_
71	,	_	_	,	_	_	_	_	_
72	and	_	_	CC	_	_	_	_	_
73	neurodegenerative	_	_	JJ	_	_	_	_	_
74	diseases	_	_	NNS	_	_	_	_	_
75	.	_	_	.	_	_	_	_	_


1	All	_	_	PDT	_	_	_	_	_
2	these	_	_	DT	_	_	_	_	_
3	complications	_	_	NNS	_	_	_	_	_
4	lead	_	_	VBP	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	shortened	_	_	VBN	_	_	_	_	_
8	life	_	_	NN	_	_	_	_	_
9	expectancy	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	have	_	_	VBP	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	high	_	_	JJ	_	_	_	_	_
14	economic	_	_	JJ	_	_	_	_	_
15	impact	_	_	NN	_	_	_	_	_
16	on	_	_	IN	_	_	_	_	_
17	healthcare	_	_	NN	_	_	_	_	_
18	systems	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Lifestyle	_	_	NN	_	_	_	_	_
2	changes	_	_	NNS	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	such	_	_	JJ	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	diet	_	_	NN	_	_	_	_	_
7	modification	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	physical	_	_	JJ	_	_	_	_	_
10	activity	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	behavioral	_	_	JJ	_	_	_	_	_
14	interventions	_	_	NNS	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	are	_	_	VBP	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	cornerstones	_	_	NNS	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	obesity	_	_	NN	_	_	_	_	_
21	treatment	_	_	NN	_	_	_	_	_
22	but	_	_	CC	_	_	_	_	_
23	maintaining	_	_	VBG	_	_	_	_	_
24	a	_	_	DT	_	_	_	_	_
25	healthy	_	_	JJ	_	_	_	_	_
26	lifestyle	_	_	NN	_	_	_	_	_
27	is	_	_	VBZ	_	_	_	_	_
28	often	_	_	RB	_	_	_	_	_
29	perceived	_	_	VBN	_	_	_	_	_
30	as	_	_	IN	_	_	_	_	_
31	challenging	_	_	JJ	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Alternatively	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	pharmacotherapy	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	bariatric	_	_	JJ	_	_	_	_	_
6	surgery	_	_	NN	_	_	_	_	_
7	represent	_	_	VBP	_	_	_	_	_
8	more	_	_	JJR	_	_	_	_	_
9	“	_	_	``	_	_	_	_	_
10	aggressive	_	_	JJ	_	_	_	_	_
11	”	_	_	''	_	_	_	_	_
12	interventions	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	are	_	_	VBP	_	_	_	_	_
16	applicable	_	_	JJ	_	_	_	_	_
17	only	_	_	RB	_	_	_	_	_
18	if	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	problem	_	_	NN	_	_	_	_	_
21	is	_	_	VBZ	_	_	_	_	_
22	severe	_	_	JJ	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Current	_	_	JJ	_	_	_	_	_
2	pharmacotherapy	_	_	NN	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	obesity	_	_	NN	_	_	_	_	_
5	relies	_	_	VBZ	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	few	_	_	JJ	_	_	_	_	_
9	drugs	_	_	NNS	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	approved	_	_	VBN	_	_	_	_	_
13	only	_	_	RB	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	patients	_	_	NNS	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	BMI	_	_	NNP	_	_	_	_	_
18	>	_	_	SYM	_	_	_	_	_
19	30.	_	_	CD	_	_	_	_	_


1	With	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	only	_	_	JJ	_	_	_	_	_
4	exception	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	orlistat	_	_	NN	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	which	_	_	WDT	_	_	_	_	_
9	decreases	_	_	VBZ	_	_	_	_	_
10	fat	_	_	NN	_	_	_	_	_
11	absorption	_	_	NN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	inhibiting	_	_	VBG	_	_	_	_	_
14	lipases	_	_	NNS	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	most	_	_	JJS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	these	_	_	DT	_	_	_	_	_
20	drugs	_	_	NNS	_	_	_	_	_
21	act	_	_	VBP	_	_	_	_	_
22	through	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	central	_	_	JJ	_	_	_	_	_
25	nervous	_	_	JJ	_	_	_	_	_
26	system	_	_	NN	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	reduce	_	_	VB	_	_	_	_	_
29	food	_	_	NN	_	_	_	_	_
30	intake	_	_	NN	_	_	_	_	_
31	(	_	_	-LRB-	_	_	_	_	_
32	via	_	_	IN	_	_	_	_	_
33	reduction	_	_	NN	_	_	_	_	_
34	of	_	_	IN	_	_	_	_	_
35	appetite	_	_	NN	_	_	_	_	_
36	or	_	_	CC	_	_	_	_	_
37	enhancement	_	_	NN	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	satiety	_	_	NN	_	_	_	_	_
40	)	_	_	-RRB-	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	use	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	these	_	_	DT	_	_	_	_	_
7	treatments	_	_	NNS	_	_	_	_	_
8	may	_	_	MD	_	_	_	_	_
9	lead	_	_	VB	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	severe	_	_	JJ	_	_	_	_	_
12	adverse	_	_	JJ	_	_	_	_	_
13	effects	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	long-term	_	_	JJ	_	_	_	_	_
17	prescription	_	_	NN	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	usually	_	_	RB	_	_	_	_	_
20	not	_	_	RB	_	_	_	_	_
21	recommended	_	_	VBN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	nutraceutical	_	_	JJ	_	_	_	_	_
3	approach	_	_	NN	_	_	_	_	_
4	could	_	_	MD	_	_	_	_	_
5	be	_	_	VB	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	useful	_	_	JJ	_	_	_	_	_
8	supporting	_	_	VBG	_	_	_	_	_
9	tool	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	treat	_	_	VB	_	_	_	_	_
12	overweight	_	_	JJ	_	_	_	_	_
13	people	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	since	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	use	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	natural	_	_	JJ	_	_	_	_	_
20	compounds	_	_	NNS	_	_	_	_	_
21	offers	_	_	VBZ	_	_	_	_	_
22	clear	_	_	JJ	_	_	_	_	_
23	advantages	_	_	NNS	_	_	_	_	_
24	over	_	_	IN	_	_	_	_	_
25	drug	_	_	NN	_	_	_	_	_
26	treatments	_	_	NNS	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	terms	_	_	NNS	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	adverse	_	_	JJ	_	_	_	_	_
31	side	_	_	NN	_	_	_	_	_
32	effects	_	_	NNS	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	suitability	_	_	NN	_	_	_	_	_
35	for	_	_	IN	_	_	_	_	_
36	chronic	_	_	JJ	_	_	_	_	_
37	treatments	_	_	NNS	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	marketability	_	_	NN	_	_	_	_	_
40	,	_	_	,	_	_	_	_	_
41	and	_	_	CC	_	_	_	_	_
42	safety	_	_	NN	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	Here	_	_	RB	_	_	_	_	_
2	we	_	_	PRP	_	_	_	_	_
3	focus	_	_	VBP	_	_	_	_	_
4	our	_	_	PRP$	_	_	_	_	_
5	attention	_	_	NN	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	pterostilbene	_	_	NN	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	Pt	_	_	NNP	_	_	_	_	_
10	;	_	_	:	_	_	_	_	_
11	3,5-dimethylresveratrol	_	_	NN	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	an	_	_	DT	_	_	_	_	_
15	analogue	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	resveratrol	_	_	NN	_	_	_	_	_
18	that	_	_	WDT	_	_	_	_	_
19	differs	_	_	VBZ	_	_	_	_	_
20	from	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	latter	_	_	NN	_	_	_	_	_
23	for	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	presence	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	two	_	_	CD	_	_	_	_	_
28	methyl	_	_	NN	_	_	_	_	_
29	groups	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Its	_	_	PRP$	_	_	_	_	_
2	increased	_	_	VBN	_	_	_	_	_
3	lipophilicity	_	_	NN	_	_	_	_	_
4	accounts	_	_	VBZ	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	its	_	_	PRP$	_	_	_	_	_
7	ability	_	_	NN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	reach	_	_	VB	_	_	_	_	_
10	higher	_	_	JJR	_	_	_	_	_
11	tissue	_	_	NN	_	_	_	_	_
12	levels	_	_	NNS	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	comparison	_	_	NN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	resveratrol	_	_	NN	_	_	_	_	_
17	’s	_	_	POS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	there	_	_	EX	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	no	_	_	DT	_	_	_	_	_
6	concern	_	_	NN	_	_	_	_	_
7	about	_	_	IN	_	_	_	_	_
8	its	_	_	PRP$	_	_	_	_	_
9	safety	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	Pterostilbene	_	_	NNP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	already	_	_	RB	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	shown	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	have	_	_	VB	_	_	_	_	_
8	positive	_	_	JJ	_	_	_	_	_
9	effects	_	_	NNS	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	combating	_	_	VBG	_	_	_	_	_
12	obesity	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	related	_	_	JJ	_	_	_	_	_
15	disorders	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	rat	_	_	NN	_	_	_	_	_
3	models	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	obesity	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	Pt	_	_	NN	_	_	_	_	_
8	reduces	_	_	VBZ	_	_	_	_	_
9	fat	_	_	JJ	_	_	_	_	_
10	accumulation	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	ameliorates	_	_	VBZ	_	_	_	_	_
13	liver	_	_	NN	_	_	_	_	_
14	steatosis	_	_	NN	_	_	_	_	_
15	modulating	_	_	VBG	_	_	_	_	_
16	lipolysis	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	lipogenesis	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	fatty	_	_	NN	_	_	_	_	_
21	acid	_	_	NN	_	_	_	_	_
22	oxidation	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	improves	_	_	VBZ	_	_	_	_	_
25	glycemic	_	_	JJ	_	_	_	_	_
26	control	_	_	NN	_	_	_	_	_
27	by	_	_	IN	_	_	_	_	_
28	modulating	_	_	VBG	_	_	_	_	_
29	glycolysis	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	gluconeogenesis	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	glucose	_	_	NN	_	_	_	_	_
35	uptake	_	_	NN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	increases	_	_	VBZ	_	_	_	_	_
38	thermogenic	_	_	JJ	_	_	_	_	_
39	markers	_	_	NNS	_	_	_	_	_
40	in	_	_	IN	_	_	_	_	_
41	brown	_	_	JJ	_	_	_	_	_
42	adipose	_	_	NN	_	_	_	_	_
43	tissue	_	_	NN	_	_	_	_	_
44	,	_	_	,	_	_	_	_	_
45	and	_	_	CC	_	_	_	_	_
46	induces	_	_	VBZ	_	_	_	_	_
47	changes	_	_	NNS	_	_	_	_	_
48	in	_	_	IN	_	_	_	_	_
49	the	_	_	DT	_	_	_	_	_
50	gut	_	_	NN	_	_	_	_	_
51	microbiota	_	_	NN	_	_	_	_	_
52	towards	_	_	IN	_	_	_	_	_
53	a	_	_	DT	_	_	_	_	_
54	healthier	_	_	JJR	_	_	_	_	_
55	composition	_	_	NN	_	_	_	_	_
56	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	Pt	_	_	NNP	_	_	_	_	_
4	exerts	_	_	VBZ	_	_	_	_	_
5	its	_	_	PRP$	_	_	_	_	_
6	beneficial	_	_	JJ	_	_	_	_	_
7	effects	_	_	NNS	_	_	_	_	_
8	combating	_	_	VBG	_	_	_	_	_
9	adipose	_	_	NN	_	_	_	_	_
10	tissue	_	_	NN	_	_	_	_	_
11	inflammation	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	An	_	_	DT	_	_	_	_	_
2	interesting	_	_	JJ	_	_	_	_	_
3	therapeutic	_	_	JJ	_	_	_	_	_
4	target	_	_	NN	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	treating	_	_	VBG	_	_	_	_	_
7	obesity	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	metabolic	_	_	JJ	_	_	_	_	_
10	syndrome	_	_	NN	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	represented	_	_	VBN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	beige	_	_	NN	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	or	_	_	CC	_	_	_	_	_
17	brite	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	i.	_	_	FW	_	_	_	_	_
20	e.	_	_	FW	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	brown-in-white	_	_	JJ	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	adipocytes	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	cells	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	an	_	_	DT	_	_	_	_	_
5	inducible	_	_	JJ	_	_	_	_	_
6	form	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	thermogenic	_	_	JJ	_	_	_	_	_
9	adipocytes	_	_	NNS	_	_	_	_	_
10	residing	_	_	VBG	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	subcutaneous	_	_	JJ	_	_	_	_	_
13	white	_	_	JJ	_	_	_	_	_
14	adipose	_	_	NN	_	_	_	_	_
15	tissue	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	WAT	_	_	NN	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	are	_	_	VBP	_	_	_	_	_
21	also	_	_	RB	_	_	_	_	_
22	found	_	_	VBN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	human	_	_	JJ	_	_	_	_	_
25	adults	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Beige	_	_	JJ	_	_	_	_	_
2	adipocytes	_	_	NNS	_	_	_	_	_
3	can	_	_	MD	_	_	_	_	_
4	derive	_	_	VB	_	_	_	_	_
5	from	_	_	IN	_	_	_	_	_
6	white	_	_	JJ	_	_	_	_	_
7	adipocyte	_	_	NN	_	_	_	_	_
8	trans	_	_	NN	_	_	_	_	_
9	differentiation	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	from	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	differentiation	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	adipogenic	_	_	JJ	_	_	_	_	_
16	progenitor	_	_	NN	_	_	_	_	_
17	cells	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	express	_	_	VBP	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	set	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	beige-specific	_	_	JJ	_	_	_	_	_
7	genes	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	such	_	_	JJ	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	Cited1	_	_	NNP	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	Tbx1	_	_	NNP	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	but	_	_	CC	_	_	_	_	_
16	also	_	_	RB	_	_	_	_	_
17	have	_	_	VBP	_	_	_	_	_
18	similarities	_	_	NNS	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	brown	_	_	JJ	_	_	_	_	_
21	adipocytes	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	including	_	_	VBG	_	_	_	_	_
24	abundant	_	_	JJ	_	_	_	_	_
25	mitochondria	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	multilocular	_	_	JJ	_	_	_	_	_
28	lipid	_	_	NN	_	_	_	_	_
29	droplets	_	_	NNS	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	expression	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	brown-specific	_	_	JJ	_	_	_	_	_
34	genes	_	_	NNS	_	_	_	_	_
35	such	_	_	JJ	_	_	_	_	_
36	as	_	_	IN	_	_	_	_	_
37	uncoupling	_	_	VBG	_	_	_	_	_
38	protein	_	_	NN	_	_	_	_	_
39	1	_	_	CD	_	_	_	_	_
40	(	_	_	-LRB-	_	_	_	_	_
41	UCP1	_	_	NN	_	_	_	_	_
42	)	_	_	-RRB-	_	_	_	_	_
43	and	_	_	CC	_	_	_	_	_
44	Cidea	_	_	NN	_	_	_	_	_
45	;	_	_	:	_	_	_	_	_
46	similar	_	_	JJ	_	_	_	_	_
47	to	_	_	TO	_	_	_	_	_
48	brown	_	_	JJ	_	_	_	_	_
49	adipocytes	_	_	NNS	_	_	_	_	_
50	,	_	_	,	_	_	_	_	_
51	they	_	_	PRP	_	_	_	_	_
52	are	_	_	VBP	_	_	_	_	_
53	able	_	_	JJ	_	_	_	_	_
54	to	_	_	TO	_	_	_	_	_
55	dissipate	_	_	VB	_	_	_	_	_
56	energy	_	_	NN	_	_	_	_	_
57	as	_	_	IN	_	_	_	_	_
58	heat	_	_	NN	_	_	_	_	_
59	.	_	_	.	_	_	_	_	_


1	Induction	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	beige	_	_	NN	_	_	_	_	_
4	adipocytes	_	_	NNS	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	i.	_	_	FW	_	_	_	_	_
7	e.	_	_	FW	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	WAT	_	_	NN	_	_	_	_	_
10	browning	_	_	NN	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	can	_	_	MD	_	_	_	_	_
13	be	_	_	VB	_	_	_	_	_
14	induced	_	_	VBN	_	_	_	_	_
15	by	_	_	IN	_	_	_	_	_
16	environmental	_	_	JJ	_	_	_	_	_
17	or	_	_	CC	_	_	_	_	_
18	physiological	_	_	JJ	_	_	_	_	_
19	stimuli	_	_	NNS	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	such	_	_	JJ	_	_	_	_	_
22	as	_	_	IN	_	_	_	_	_
23	cold	_	_	JJ	_	_	_	_	_
24	exposure	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	physical	_	_	JJ	_	_	_	_	_
27	activity	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	or	_	_	CC	_	_	_	_	_
30	thyroid	_	_	NN	_	_	_	_	_
31	hormones	_	_	NNS	_	_	_	_	_
32	)	_	_	-RRB-	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	but	_	_	CC	_	_	_	_	_
35	also	_	_	RB	_	_	_	_	_
36	pharmacologically	_	_	RB	_	_	_	_	_
37	(	_	_	-LRB-	_	_	_	_	_
38	for	_	_	IN	_	_	_	_	_
39	example	_	_	NN	_	_	_	_	_
40	,	_	_	,	_	_	_	_	_
41	with	_	_	IN	_	_	_	_	_
42	PPAR	_	_	NN	_	_	_	_	_
43	agonists	_	_	NNS	_	_	_	_	_
44	)	_	_	-RRB-	_	_	_	_	_
45	,	_	_	,	_	_	_	_	_
46	and	_	_	CC	_	_	_	_	_
47	could	_	_	MD	_	_	_	_	_
48	prevent	_	_	VB	_	_	_	_	_
49	or	_	_	CC	_	_	_	_	_
50	combat	_	_	VB	_	_	_	_	_
51	obesity	_	_	NN	_	_	_	_	_
52	by	_	_	IN	_	_	_	_	_
53	increasing	_	_	VBG	_	_	_	_	_
54	energy	_	_	NN	_	_	_	_	_
55	consumption	_	_	NN	_	_	_	_	_
56	through	_	_	IN	_	_	_	_	_
57	non-shivering	_	_	JJ	_	_	_	_	_
58	thermogenesis	_	_	NN	_	_	_	_	_
59	.	_	_	.	_	_	_	_	_


1	Various	_	_	JJ	_	_	_	_	_
2	phytochemicals	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	reported	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	promote	_	_	VB	_	_	_	_	_
8	fat	_	_	JJ	_	_	_	_	_
9	browning	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	aim	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	study	_	_	NN	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	investigate	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	ability	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	Pt	_	_	NNP	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	do	_	_	VB	_	_	_	_	_
15	it	_	_	PRP	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	WAT	_	_	NNP	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Its	_	_	PRP$	_	_	_	_	_
2	effects	_	_	NNS	_	_	_	_	_
3	were	_	_	VBD	_	_	_	_	_
4	first	_	_	RB	_	_	_	_	_
5	assayed	_	_	VBN	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	cultured	_	_	VBN	_	_	_	_	_
8	3T3-L1	_	_	NN	_	_	_	_	_
9	adipocytes	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	then	_	_	RB	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	mouse	_	_	NN	_	_	_	_	_
16	model	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	diet-induced	_	_	JJ	_	_	_	_	_
19	obesity	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	take	_	_	VB	_	_	_	_	_
3	into	_	_	IN	_	_	_	_	_
4	account	_	_	NN	_	_	_	_	_
5	possible	_	_	JJ	_	_	_	_	_
6	gender-specific	_	_	JJ	_	_	_	_	_
7	differences	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	both	_	_	DT	_	_	_	_	_
10	females	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	males	_	_	NNS	_	_	_	_	_
13	were	_	_	VBD	_	_	_	_	_
14	included	_	_	VBN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	our	_	_	PRP$	_	_	_	_	_
17	experimental	_	_	JJ	_	_	_	_	_
18	groups	_	_	NNS	_	_	_	_	_
19	;	_	_	:	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	30	_	_	CD	_	_	_	_	_
22	week-long	_	_	JJ	_	_	_	_	_
23	treatment	_	_	NN	_	_	_	_	_
24	was	_	_	VBD	_	_	_	_	_
25	performed	_	_	VBN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	highlight	_	_	VB	_	_	_	_	_
29	long-term	_	_	JJ	_	_	_	_	_
30	effects	_	_	NNS	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	a	_	_	DT	_	_	_	_	_
33	chronic	_	_	JJ	_	_	_	_	_
34	Pt	_	_	NN	_	_	_	_	_
35	supplementation	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	found	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	Pt	_	_	NNP	_	_	_	_	_
5	diminished	_	_	VBN	_	_	_	_	_
6	body	_	_	NN	_	_	_	_	_
7	weight	_	_	NN	_	_	_	_	_
8	gain	_	_	NN	_	_	_	_	_
9	induced	_	_	VBN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	high-fat	_	_	JJ	_	_	_	_	_
13	diet	_	_	NN	_	_	_	_	_
14	regimen	_	_	NN	_	_	_	_	_
15	;	_	_	:	_	_	_	_	_
16	also	_	_	RB	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	glucose	_	_	NN	_	_	_	_	_
19	homeostasis	_	_	NN	_	_	_	_	_
20	was	_	_	VBD	_	_	_	_	_
21	partially	_	_	RB	_	_	_	_	_
22	preserved	_	_	VBN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	at	_	_	IN	_	_	_	_	_
25	least	_	_	JJS	_	_	_	_	_
26	up	_	_	IN	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	week	_	_	NN	_	_	_	_	_
29	18	_	_	CD	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Interestingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	Pt	_	_	NNP	_	_	_	_	_
4	was	_	_	VBD	_	_	_	_	_
5	able	_	_	JJ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	induce	_	_	VB	_	_	_	_	_
8	WAT	_	_	NN	_	_	_	_	_
9	browning	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	leading	_	_	VBG	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	an	_	_	DT	_	_	_	_	_
14	increase	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	transcription	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	beige-	_	_	JJ	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	brown-related	_	_	JJ	_	_	_	_	_
22	genes	_	_	NNS	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	UCP1	_	_	NNP	_	_	_	_	_
26	protein	_	_	NN	_	_	_	_	_
27	levels	_	_	NNS	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	which	_	_	WDT	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	however	_	_	RB	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	did	_	_	VBD	_	_	_	_	_
34	not	_	_	RB	_	_	_	_	_
35	achieve	_	_	VB	_	_	_	_	_
36	significance	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_

